Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022

Anne J Huiberts, Brechje de Gier, Christina E Hoeve, Hester E de Melker, Susan Jm Hahné, Radboud center, Janneke Hhm van de Wijgert, Susan van den Hof, Mirjam J Knol

Research output: Contribution to journalArticleAcademicpeer-review

10 Downloads (Pure)

Abstract

We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18-59-year-olds and 14% in 60-85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.

Original languageEnglish
JournalEurosurveillance
Volume28
Issue number7
DOIs
Publication statusPublished - 16 Feb 2023

Keywords

  • COVID-19
  • SARS-CoV-2
  • vaccine effectiveness

Fingerprint

Dive into the research topics of 'Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022'. Together they form a unique fingerprint.

Cite this